Status:
UNKNOWN
Thromboelastography Guides a Multicentre Cluster Controlled Study of Plasma Exchange for Hepatitis B Associated Acute-on-chronic Liver Failure
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
28 Day Mortality
Eligibility:
All Genders
16-80 years
Phase:
NA
Brief Summary
In the past ten years, the extracorporeal liver support system has been widely used in clinical practice as a first-line treatment of liver failure. Plasma exchange (PE) can remove toxic substances in...
Eligibility Criteria
Inclusion
- 1\) 18-80 years old; 2) Chronic HBV infection related: HBsAg positive for more than 6 months; 3) EASL-ACLF grade 2
Exclusion
- 1\) Other causes of chronic liver disease; 2) Active bleeding and diffuse intravascular coagulation; 3) Those who have been severely allergic to blood products and heparin in the past; 4) Circulatory failure; 5) Respiratory failure; 6) Patients with unstable period of cardiovascular and cerebrovascular infarction; 7) Those who have received platelet transfusion or artificial liver within 1 week; 8) Patients with liver cancer or other malignant tumors; 9) Pregnant and lactating women; 10) Those with other serious chronic diseases; 11) Fail to sign the informed consent form; 12) Circumstances that the researcher considers inappropriate to participate in the research.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2021
Estimated Enrollment :
390 Patients enrolled
Trial Details
Trial ID
NCT04747106
Start Date
July 1 2020
End Date
April 30 2021
Last Update
February 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital
Guangzhou, Guangdong, China, 510515